It’s time for another edition of Reading Roundup featuring the top blog posts of June 2017. Start off your week by catching up on what the pharmaceutical industry was reading in June.

Extractables and Leachables: Not the Same – Part 2

As a follow-up to Extractables and Leachables: Not the Same – Part 1, this article details the QbD approach, and extractable and leachable evaluation methodology. Read Extractables and Leachables: Not the Same – Part 2 to learn more about the principles that will facilitate single-unit system (SUS) implementation. This article can also be found in the May/June edition of Pharmaceutical Engineering® magazine.


5 Megatrends in Biotechnological Factories of the Future

At the 2017 ISPE Europe Biotechnology Conference in Dublin, top pharmaceutical industry professionals and the National Institute for Bioresearch and Technology (NIBRT) will address the growth of biologics and its future impact. Find out more about the five major trends in biotechnology that will be addressed at the conference.


It’s Go Time! Where is Pharma at with Implementing Serialization?

At the 2017 ISPE Pharmaceutical Serialization Workshop in Philadelphia, Pennsylvania, representatives from Johnson & Johnson, Pfizer, Eli Lily, and other companies delivered presentations on where their companies stand on implementing serialization. Learn more about their findings and thoughts on implementing serialization.


Celebrating the Best of the Best in Pharma and Biotech Manufacturing Facilities

The 13th Annual Facility of the Year Awards (FOYA) banquet took place on Tuesday, 6 June in Arlington, Virginia. Find out more about this year’s celebration, the winners, and their award-winning projects.


2017 Quality Manufacturing Conference- FDA Regulatory Round Table

The last featured session of the 2017 ISPE/FDA/PQRI Quality Manufacturing Conference was the Regulatory round table on 7 June. Find out how a panel of FDA regulators responded when conference participants asked about topics such as quality metrics and the future of FDA regulation.

RELATED POSTS